课题基金 / 基金详情

CAP18-IGG FUSION PROTEIN--A NOVEL TREATMENT FOR SEPSIS

CAP18-IGG FUSION PROTEIN--A NOVEL TREATMENT FOR SEPSIS
CAP18-IGG 融合蛋白——脓毒症的新型治疗方法
批准号:
2887178
负责人:
H Shaw Warren
金额:
$31.79万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-08-01 至 2001-07-31

项目摘要

项目成果

H Shaw Warren的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Adapted from the applicant's abstract) Gram-negative infections continue to cause substantial morbidity and mortality. A major part of the toxicity from these infections is believed to be caused by lipopolysaccharide (LPS) release from dying bacteria, that interacts with host systems leading to secondary inflammation. The availability of an agent with a long half-life that is capable of both killing Gram-negative bacteria and neutralizing its endotoxin would be a major advance which may prove to be therapeutically advantageous. Chemical conjugates of an 18 kD cationic protein present in human granulocytes (CAP18) coupled to human IgG appears to be such an agent. CAP18-IgG fusion proteins are believed to function by binding LPS that is present on or is released from the bacterial cell wall. Bacterial killing is presumed to occur by intercalation and disruption of the outer cell membrane. In preliminary studies CAP18-IgG fusion proteins appear to kill a wide variety of Gram-negative bacteria as well as neutralize bacterial LPS. This study seeks to develop and evaluate the efficacy of fusion proteins of CAP18 conjugated with the human heavy chain IgG in gram negative infections. In order to accomplish this goal the following series of experiments are proposed: 1) Design, construct, express, and purify fusion proteins of CAP18-IgG and CAP18104-135-IgG. 2) Characterize and assess the in vitro ability of these CAP18-IgG fusion proteins to bind and neutralize Gram-negative bacteria and LPS, assess their bactericidal activity, promote opsinophagocytosis of bacteria and bacterial membrane, and determine stability in blood over time. 3) Evaluate these CAP18-IgG fusion proteins in vivo using rabbits and rats to determine their pharmacokinetics, their functional stability in the bloodstream over time and ability to clear radiolabeled LPS and bacteria from the blood. 4) Study the protection by the best CAP18-IgG fusion proteins in two models of Gram-negative sepsis: a) Gram-negative infection in rats made neutropenic with cyclophosphamide, and b) a rat model of peritoneal sepsis.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Binding of a dimeric derivative of vancomycin to L-Lys-D-Ala-D-lactate in solution and at a surface.
万古霉素二聚体衍生物在溶液中和表面与 L-Lys-D-Ala-D-乳酸结合。
DOI: 10.1016/s1074-5521(99)80047-7
发表时间: 1999
期刊: Chemistry & biology.
影响因子: --
作者: [Rao,J, Yan,L, Lahiri,J, Whitesides,GM, Weis,RM, Warren,HS]
通讯作者: Warren,HS
PROTEOMIC CHARACTERIZATION OF CEREBROSPINAL FLUID BY HIGH RESOLUTION LC-MS/MS
PROTEOMIC CHARACTERIZATION OF CEREBROSPINAL FLUID BY HIGH RESOLUTION LC-MS/MS
PROTEOMIC CHARACTERIZATION OF CEREBROSPINAL FLUID BY HIGH RESOLUTION LC-MS/MS
PROTEOMIC CHARACTERIZATION OF CEREBROSPINAL FLUID BY HIGH RESOLUTION LC-MS/MS
海外基金